Citation: Jw. Eschbach, ORAL IRON THERAPY IN HEMODIALYSIS-PATIENTS AND THE NEW NKF-DOQI CLINICAL-PRACTICE GUIDELINES - REPLY, American journal of kidney diseases, 31(3), 1998, pp. 557-558
Authors:
DRUEKE TB
BARANY P
CAZZOLA M
ESCHBACH JW
GRUTZMACHER P
KALTWASSER JP
MACDOUGALL IC
PIPPARD MJ
SHALDON S
VANWYCK D
Citation: Tb. Drueke et al., MANAGEMENT OF IRON-DEFICIENCY IN RENAL ANEMIA - GUIDELINES FOR THE OPTIMAL THERAPEUTIC APPROACH IN ERYTHROPOIETIN-TREATED PATIENTS, Clinical nephrology, 48(1), 1997, pp. 1-8
Authors:
VALDERRABANO F
MADIAS NE
SCHENA FP
CARRERA F
SILVERBERG D
KOKOT F
ZUCCHELLI P
CANNATA J
ESCHBACH JW
MALLICK NP
SELVAGGI G
TEPLAN V
EFSTRATOPOULOS AD
CHANG JM
VISWESWARAN K
HURWICH B
PAPADIMITRIOU M
LASKER N
MATHEW T
Citation: F. Valderrabano et al., ERYTHROPOIETIN IN CHRONIC-RENAL-FAILURE, Kidney international, 50(4), 1996, pp. 1373-1391
Authors:
PAGANINI EP
ESCHBACH JW
LAZARUS JM
VANSTONE JC
GIMENEZ LF
GRABER SE
EGRIE JC
OKAMOTO DM
GOODKIN DA
Citation: Ep. Paganini et al., INTRAVENOUS VERSUS SUBCUTANEOUS DOSING OF EPOETIN ALFA IN HEMODIALYSIS-PATIENTS, American journal of kidney diseases, 26(2), 1995, pp. 331-340
Citation: Jw. Eschbach, DOES TREATMENT WITH ERYTHROPOIETIN CAUSE VASCULAR ACCESS THROMBOSIS -ERYTHROPOIETIN IS NOT A CAUSE OF ACCESS THROMBOSIS, Seminars in dialysis, 6(3), 1993, pp. 180-184